Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT02535338

Public ClinicalTrials.gov record NCT02535338. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 6:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer

Study identification

NCT ID: NCT02535338
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 11 participants

Conditions and interventions

Conditions

Interventions

Erlotinib Hydrochloride Drug
Laboratory Biomarker Analysis Other
Onalespib Lactate Drug
Pharmacological Study Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 10, 2016
Primary completion: Sep 2, 2021
Completion: Sep 7, 2021
Last update posted: Mar 2, 2025

2016 – 2021

United States locations

U.S. sites: 6
U.S. states: 1
U.S. cities: 5

Facility	City	State	ZIP	Site status
City of Hope Comprehensive Cancer Center	Duarte	California	91010	—
Los Angeles General Medical Center	Los Angeles	California	90033	—
USC / Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
Keck Medical Center of USC Pasadena	Pasadena	California	91105	—
University of California Davis Comprehensive Cancer Center	Sacramento	California	95817	—
City of Hope South Pasadena	South Pasadena	California	91030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02535338, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 2, 2025 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02535338 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →